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6-Mercaptopurine (6-MP*) and its imidazole derivative, 
azathioprine (AZ), are clinically useful immunosuppressive 
agents. A Z  in particular has gained widespread use and has 
been cited as "the most widely used cytotoxic 
immunosuppressive agent in clinical medicine" [1]. The 
biochemical and metabolic effects of these thiopurines have 
been reviewed [1--4]. However, the precise mechanism of 
their immunosuppressive activity is not clearly understood 
[1,2]. 
The cytotoxicity of 6-MP is dependent upon its phos- 
phoribosylation to thioinosinic acid (TIMP) which is cata- 
lyzed by the enzyme hypoxanthine-guanine phospho- 
ribosyltransferase (HPRT, EC 2.4.2.8). Cell lines which 
are resistant to 6-MP have been shown to lack HPRT 
activity [5], and neither 6-MP nor A Z  has activity in HPRT- 
deficient patients [6]. TIMP is an effective inhibitor of 
purine nucleotide biosynthesis and interconversion (see 
Fig. 1). It is a competitive inhibitor of adenylsuccinate 
synthetase, adenylsuccinate lyase, and IMP dehydro- 
genase, and it is a pseudo feedback inhibitor of glutamine- 
phosphoribosylpyrophosphate amidotransferase, the first 
enzyme unique to the de novo purine nucleotide biosyn- 
thetic pathway [3,4]. Other effects of TIMP include in- 
corporation into nucleic acid, the inhibition of coenzyme 
formation and function, and the inhibition of protein syn- 
thesis [3,4]. 
Many of the metabolic effects of A Z  are dependent upon 
its cleavage to 6-MP and the subsequent phosporibosylation 
to TIMP. However, there has been increasing evidence 
which indicates that A Z  has metabolic effects which may 
account for its distinct and more widespread clinical appli- 
* Abbreviations: 6-MP, 6-mercaptopurine; AZ, 
azathioprine; TIMP, thioinosinic acid; and HPRT, hypo- 
xanthine-guanine phosphoribosylatransferase. 
cability as an immunosuppressant as compared to 6-MP 
[1--4,7,8]. These effects might be attributable to biologically 
active metabolites unique to AZ or could possibly be due 
to the reaction of the methylnitroimidazole moiety with 
active metabolites or with potentially reactive groups on 
cellular proteins [2]. 
In this study, utilizing HPRT ÷ and HPRT-deficient 
human lymphoblastoid cell lines, we have found evidence 
which suggests that the cytotoxicity of A Z  in cell culture, 
unlike that of 6-MP, is, in part, independent of HPRT 
activity. 
Materials and methods 
Chemicals. Azathioprine, 6-mercaptopurine, glutamine 
and the purine nucleosides and bases used were purchased 
from the Sigma Chemical Co. Heat-inactivated horse serum 
and RPMI 1640 medium were purchased from the Grand 
Island Biological Co. RPMI 1640 contains glutathione 
(1 mg/l) as one of its components. 
Cell lines. Human lymphoblastoid cell lines were main- 
tained in RPM11640 medium supplemented with 10% heat- 
inactivated horse serum and 2 mM glutamine. The MGL- 
8 cell line (HPRT ÷) was derived from a normal individual 
and was a gift from J. Epstein, Johns Hopkins University. 
The GM-130 cell line, derived from a normal individual, 
and the GM-467 (HPRT-deficient, mutagenized) cell line 
were obtained from the Human Genetics Mutant Cell 
Repository. The HPRT-deficient cell line HD was derived 
from a patient presenting with the Lesch-Nyhan Syndrome 
by Epstein-Barr virus transformation by the method 
described previously [9]. The MOLT-4 cell line (HPRT+), 
originally derived from a patient presenting with the Lesch- 
Nyhan Syndrome by Epstein-Barr virus transformation by 
the method described previously [9]. The MOLT-4 cell line 
(HPRT÷), originally derived from a patient with acute 
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Fig. 1. Purine metabolic pathways. The phosphoribosylation of 6-MP to thioinosinic acid (TIMP) is 
catalyzed by (1) hypoxanthine-guanine phosphoribosyltransferase (HPRT). TIMP can potentially inter- 
fere with purine nucleotide biosynthesis by inhibiting the activities of (2) phosphoribosylpyrophosphate 
amidotransferase, (3) IMP dehydrogenase, (4) adenylsuccinate synthetase, ~/nd (5) adenylsuccinate lyase 
[2-4]. 
lymphoblastic leukemia, was obtained from HEM 
Research. The levels of HPRT enzyme activity in the MGL- 
8 and GM-130 cell lines were reported to be 18.4 -+ 1.5 and 
11.4 - 2.5 mU/mg, respectively, while the levels of HPRT 
immunoreactive protein in these cell lines were reported 
as 442 -+ 45 and 264 - 19 ng HPRT/mg respectively [9]. 
Using similar methodology, the GM-467 and HD cell lines 
were found to have undetectable HPRT enzyme activity or 
HPRT immunoreactive protein (data not shown). 
Growth studies. All lymphoblast growth studies were 
initiated at a cell density of approximately 2.0 x 1@ cells/ 
ml. After 3 days of incubation at 37 °, viable cells were 
counted using a hemacytometer, with trypan blue dye 
exclusion used as an index of viability. The toxic effects of 
AZ and 6-MP on the growth of HPRT + and HPRT-deficient 
human lymphoblasts were evaluated by determining the 
concentration of each drug at which there was a 50% 
reduction in the control cell density after 3 days of incu- 
bation 0c50). 
Results and discussion 
The effects of 6-MP and A Z  on the growth of normal 
(HPRT ÷) and HPRT-deficient human lymphoblasts are 
summarized in Table 1 and in Fig. 2. The HPRT ÷ lympho- 
blasts were sensitive to both 6-MP and AZ, with AZ 
appearing to be somewhat less toxic than 6-MP at equimolar 
doses, especially in the HPRT ÷ T lymphoblasts. The 
average Ics0 values of 6-MP and A Z  for the HPRT ÷ B cells 
were 1.8 and 3.8/~M respectively. In the HPRT + T cell 
line, MOLT-4, the Ics0 for 6-MP was 1.0/tM and for AZ, 
7.6/zM. The lower toxicity of A Z  as compared to 6-MP at 
equivalent doses is in accordance with previous reports, 
and has been postulated as an explanation for the reported 
clinical efficacy of A Z  as compared to 6-MP [2]. As 
expected, based on the inability of the ceils to convert 6- 
MP to thioinosinic acid, the growth of the HPRT-deficient 
B lymphoblast cultures was unaffected by 6-MP con- 
centrations as high as 200/~M, the highest concentration 
used in these experiments. However, A Z  was found to be 
toxic to both the chemically mutagnenized HPRT-deficient 
B cell line (GM-467) and the B lymphoblastoid cell line 
derived from a patient presenting with the Lesch-Nyhan 
Syndrome (HD), with respective IC50 values of 30 and 
32/JM. These values are approximately 8-fold higher than 
the Ics0 values for the HPRT + B lymphoblasts, indicating 
that there was some resistance to the toxic effects of A Z  in 
the HPRT-deficient cells; however, these cell lines were 
resistant to 6-MP concentrations at least 100-fold greater 
than the Ic50 of 6-MP for the HPRT ÷ B lymphoblasts. The 
discrepancy between the resistance of the HPRT-deficient 
cells to 6-MP and A Z  indicates that, unlike the toxicity of 
6-MP, the toxicity of A Z  at concentrations greater than 
25/tIVI was independent of HPRT activity. 
Supplementation of cultures with either adenine or ino- 
sine protected HPRT ÷ lymphoblasts from growth inhibition 
by 6-MP at concentrations at least as high as 180/~M (Table 
1 and Fig. 2A). Supplementation of cultures with adeno- 
sine, deoxyadenosine, deoxyinosine, or hypoxanthine 
similarly protected these cells from growth inhibition by 
6-MP (data not shown). However, supplementation of 
cultures with guanosine, deoxyguanosine, or xanthosine 
did not appear to affect the toxicity of 6-MP (data not 
shown). Both guanosine and deoxyguanosine can be con- 
verted to guanine in these cells. Because guanine and 
hypoxanthine are both substrates for HPRT, it is highly 
unlikely that the effect of the other purines was due solely 
to competition for HPRT by hypoxathine accumulated as 
a metabolite of these purines. The principal mechanism by 
which the metabolites of 6-MP exert toxicity is through 
the inhibition of de novo purine biosynthesis and purine 
nucleotide interconversions [1-4]. The purines which pro- 
tect the cells from the toxicity of 6-MP can be utilized by 
the purine salvage and nucleotide interconversion pathways 
in the HPRT ÷ lymphoblasts to form both adenine and 
guanine nucleotides (Fig. 1). However, guanosine and 
deoxyguanosine can only be utilized to form guanine 
nueleotides as the ability to convert guanine nucleotides to 
adenine nucleotides is absent in mammalian cells [10]. It 
appears most likely that, by providing an alternative source 
for purine nucleotide synthesis, purine supplementation 
protects the cells from effects of the inhibition of the de 
novo purine biosynthetic pathway by TIMP and other 
metabolites of 6-MP. 
The addition of 50/dVl inosine or adenine to cultures of 
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HPRT ÷ B lymphoblasts incubated with 6-MP raised the 
Ics0 for 6-MP in these cell lines by over 100-fold (from 1.8 
to >180/~M for 50/zM inosine and to >180/dVl for 50 gM 
adenine). Higher concentrations of inosine further pro- 
tected the cells from growth inhibition by 6-MP (Fig. 2A). 
In contrast, when 50 pM adenine or inosine was added to 
cultures of HPRT ÷ B lymphoblasts incubated with AZ, the 
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Fig. 2. Effect of inosine on the toxicity of (A) 6-MP and 
(B) A Z  in normal (HPRT ÷) B lymphoblasts (MGL-8). The 
effect of each drug alone (O---- -~)  is compared to the 
effect of the drug in the presence of 50/AVI inosine 
(O O) and, for 6-MP, 100/AVl inosine (A A). 
There was little difference between the effects of 100/aM 
inosine and 50 #M inosine on the toxicity of A Z  (see 
Table 1). 
(Table 1 and Fig. 2B). Higher concentrations of either 
adenine or inosine did not further affect the toxicity of AZ. 
Interestingly, the Ic5o values of A Z  for the HPRT ÷ cell lines 
supplemented with adenine or inosine are comparable to 
those observed in the HPRT-deficient cell lines. Neither 
adenine nor inosine had any marked effect on the growth 
inhibition of the HPRT-deficient lymphoblasts by AZ. 
Although inosine cannot be utilized as a purine source in 
HPRT-deficient cells since B lymphoblasts lack the ability 
to phosphorylate inosine, adenine can be utilized in these 
cells to form both adenine and guanine nucleotides. In 
addition we observed no effect on the toxicity of A Z  from 
the addition of 50 gM adenine to cultures of an adenine 
phosphoribosyltransferase (EC 2.4.2.7)-deficient human B 
lymphoblast cell line which cannot utilize adenine to form 
purine nucleotides. In contrast, 50 #M inosine raised the 
tcs0 of A Z  in this cell line from 2.7 to 39 #M. Again, this 
is comparable to the ICso of A Z  in the HPRT-deficient cell 
lines. In the HPRT ÷ lymphoblasts, supplementing cultures 
with adenosine, deoxydenosine, deoxyinosine or hypo- 
xanthine had effects on the toxicity of AZ which were 
similar to those of adenine and inosine, and supplementing 
the cultures with guanosine, deoxyguanosine or xanthosine 
did not appear to affect A Z  toxicity (data not shown). 
Again, only supplementation of cultures with purines which 
can be utilized to form both adenine and guanine nucleo- 
tides affects the toxicity of AZ. These results suggest that 
the addition of purine relieves only the HPRT-dependent 
toxicity of AZ,  presumably by circumventing the effects 
of the inhibition of de n o v o  purine biosynthesis and/or 
nucleotide interconversions. Because added purines do not 
protect cells from the HPRT-independent effects of AZ, 
these effects are probably not directly due to purine nucleo- 
tide depletion. 
The data presented in this communication strongly sug- 
gest that the cytotoxicity of AZ, unlike that of 6-MP, is, in 
part, independent of HPRT activity. The HPRT-inde- 
pendent toxicity of A Z  was not affected by purine sup- 
plementation and is therefore unlikely to be associated with 
the inhibition of de n o v o  purine biosynthetic or inter- 
conversion pathways. The culture medium concentrations 
at which the HPRT-independent toxicity of AZ exceeds 
the reported therapeutic plasma range concentration 
(upper limit 7 #M [2]) for A Z  in man, and the relationship 
of our observations to clinical differences between A Z  and 
6-MP, remain unestablished. A preliminary report of our 
results was presented earlier [11]. 
Table 1. Effects of 6-MP and A Z  on the growth of normal (HPRT ÷) and HPRT-deficient human lymphoblasts* 
ICs0 (~M) 
6-Mercaptopurine Azathioprine 
+ Inosine + A d e n i n e  + Inosine + Adenine 
Cell line 6-MP 50 gM 100 gM 50/zM 100/~M AZ 50/aM 100 paM 50 ~tM 100 ~M 
B lymphoblasts 
MGL-8 1.8 179 >180 >180 >180 3.7 35 42 54 38 
GM-130 1.7 >180 >180 >180 >180 4.0 40 34 43 41 
HPRT-deficient B Lymphoblasts 
GM-467 >200 . . . .  30 29 21 34 36 
HD >200 . . . .  32 31 26 46 33 
T Lymphoblasts 
MOLT-4 1.0 175 >200 >200 >200 7.6 36 41 40 34 
* The toxic effects of A Z  and 6-MP on normal (HPRT ÷) and HPRT-deficient human lymphoblasts were evaluated by 
determining the concentration of each drug which caused a 50% inhibition of the growth of the culture over a 3-day 
incubation (Ics0) relative to control cultures (no drug added). The initial cell density in these experiments was approximately 
2 x 10 ~ cells/ml. The growth of each culture was determined by subtracting the initial cell density from the cell density 
after a 3-day incubation at 37 °. Each Ics0 value represents one to eleven determinations. 
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To summarize, the toxic effects of A Z  and 6-MP on 
normal (HPRT +) and HPRT-deficient human lymphoblasts 
were evaluated. HPRT-deficient B lymphoblasts were 
resistant to 6-MP at concentrations as high as 100-fold 
greater than for HPRT + lymphoblasts. In contrast, the ICs0 
values for A Z  in the HPRT-deficient lymphoblasts were 
less than 10-fold greater than for the HPRT + B cell lines. 
The data suggest that the growth-inhibitory effects of AZ, 
unlike those of 6-MP, are, in part, independent of phos- 
phoribosylation by HPRT. We also found that sup- 
plementing the cells with a purine which could be utilized 
to form both adenine and guanine nucleotides prevented 
the FIPRT-dependent inhibition of lymphoblast growth, 
presumably by alleviating the effects of the inhibition of de 
novo purine biosynthesis. However, added purines did not 
protect the cells from the HPRT-independent effects of 
AZ, which suggests that these effects are not due to purine 
nucleotide depletion. 
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